Jazz Pharmaceuticals (JAZZ) Deferred Taxes (2012 - 2026)

Jazz Pharmaceuticals' Deferred Taxes history runs 15 years deep, the most recent figure standing at -$66.2 million for Q1 2026.

• In Q1 2026, Deferred Taxes fell 51.14% year-over-year to -$66.2 million; the TTM figure through Mar 2026 stood at -$467.4 million (down 151.62% YoY), while the FY2025 annual figure was -$445.0 million, down 113.59% from the prior year.
• Deferred Taxes was -$66.2 million for Q1 2026 at Jazz Pharmaceuticals, down from -$63.3 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of -$2.4 million in Q4 2024 to a low of -$271.4 million in Q3 2025.
• Historically, Deferred Taxes has averaged -$74.8 million across 5 years, with a median of -$66.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Deferred Taxes jumped 93.44% in 2024, then sank 2588.28% in 2025.
• A 5-year view of Deferred Taxes shows it stood at -$145.4 million in 2022, then surged by 75.31% to -$35.9 million in 2023, then surged by 93.44% to -$2.4 million in 2024, then tumbled by 2588.28% to -$63.3 million in 2025, then decreased by 4.57% to -$66.2 million in 2026.
• The last three Deferred Taxes figures came in at -$66.2 million (Q1 2026), -$63.3 million (Q4 2025), and -$271.4 million (Q3 2025), per Business Quant data.